Loading...

ATNF 180 LIFE SCIENCES CORP Investments/Divestments 8-K Filing

180

TNF

180 LIFE SCIENCES CORP

(ATNF)

2023 8-K

Show Summary

Show Summary

Asset Acquisitions

Settlement Agreement

Filing Corrections

Settlement Agreement

Management Changes

Management Changes

Stock Conversion Approval

Incentive Plan Update

CFO Resignation

Audit Committee Compliance

Management Change

Annual Meeting Notice

Director Appointment

Warrant Agreement

Warrant Agreement

Compliance Update

Asset Acquisition

Management Change

Management Changes

Extension Granted by Nasdaq

Extension Granted by Nasdaq

Resignations and Appointments

Changes in Accounting Firm

Compliance with Nasdaq List...

Resignation and Appointment...

Equity Securities Sales

Unregistered Sales of Equit...

Appointment of New Director

Reverse Stock Split

Equity Securities and Rever...

Special Meeting Approval

Departure of Directors or C...

Compensation Amendments

Non-compliance with Nasdaq ...

Resignations of Board Members

Resignation of Director

Engagement of Financial Adv...

Securities Purchase Agreeme...

MHRA Response on Phase 3 Cl...

Termination of License Agre...

Bylaws Amendment and Stock ...

Securities Purchase Agreeme...

Regulation FD Disclosure

Regulation FD Disclosure

Management Changes

Counterclaim against AmTrus...

Securities Purchase Agreement

Update on anti-TNF frozen s...

Regulation FD Disclosure

Departure of Directors or C...

Amendment to Warrant Agent ...

Warrant Issuance and Amendment

Compliance regained with mi...

Regulation FD Disclosure

External Links:

180 Life Sciences received a response from the MHRA regarding a meeting held to propose a Phase 3 clinical trial for the use of adalimumab as a therapy for Dupuytren's contracture; MHRA agreed with proposed endpoints and stated that Phase 3 study res

AI Assistant

180 LIFE SCIENCES CORP

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.